前列腺舒通胶囊联合宁泌泰胶囊治疗慢性前列腺炎疗效观察及安全性评价

发布时间：2018-06-24 16:34

本文选题：前列舒通胶囊 + 慢性前列腺炎　；参考：《中成药》2017年08期

【摘要】：目的探讨前列舒通胶囊联合宁泌泰胶囊治疗慢性前列腺炎的临床效果。方法选取112例慢性前列腺炎患者,随机均分为治疗组和对照组(n=56),对照组单独使用前列舒通胶囊治疗,治疗组给予前列舒通胶囊联合宁泌泰胶囊慢治疗,2组均治疗4周。比较2组患者治疗前后国际前列腺炎症状评分和疗效的差异。结果治疗组慢性前列腺炎症状评分(NIH-CPSI)低于对照组评分,经t检验差异有统计学意义(P0.05);治疗组治疗总有效率为94.6%,高于对照组的80.4%,经卡方检验差异有统计学意义(P0.05)。结论前列舒通胶囊联合宁泌泰胶囊治疗慢性前列腺炎效果确切,能有效降低患者国际前列腺症状评分,并且安全性好,值得临床推广使用。
[Abstract]:Objective to investigate the clinical effect of Qianlieshutong capsule combined with Ningbitai capsule in the treatment of chronic prostatitis. Methods 112 patients with chronic prostatitis were randomly divided into treatment group (n = 56) and control group (n = 56). The control group was treated with Qianlie Shutong capsule alone and the treatment group was treated with Qianlie Shutong capsule combined with Ningmitai capsule for 4 weeks. To compare the difference of international prostatitis symptom score and curative effect between the two groups before and after treatment. Results the scores of chronic prostatitis symptom (NIH-CPSI) in the treatment group were significantly lower than those in the control group (P0.05), the total effective rate of the treatment group was 94.6, which was higher than that in the control group (80.4), and the difference was statistically significant by chi-square test (P0.05). Conclusion Qianlieshutong capsule combined with Ningbetai capsule is effective in the treatment of chronic prostatitis. It can effectively reduce the international prostate symptom score of the patients and is safe and worthy of clinical popularization.
【作者单位】：贵州省遵义医学院附属医院泌尿外科;贵州省遵义医学院附属医院美容医院;
【分类号】：R277.5

【相似文献】